Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Nosocomial Bacterial and Fungal Chest Infections in Cirrhotic Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03413293
Recruitment Status : Not yet recruiting
First Posted : January 29, 2018
Last Update Posted : May 18, 2018
Sponsor:
Information provided by (Responsible Party):
NZBakhiet, Assiut University

Brief Summary:
Hospital acquired chest Infections are common complications in hospitalized cirrhotic patients. Infectious complications are the most common cause of mortality in cirrhotic patients with bronchopneumonia early antibiotic treatment at the base of culture and sensitivity is an optimal therapeutic approach in cirrhotics with nosocomial pneumonia Intensive care unit acquired pneumonia is the leading infection in critically ill patients and a major cause of morbidity and mortality despite recent major advances in antimicrobial therapy, supportive care, and the use of a broad range of preventive measures

Condition or disease Intervention/treatment
Nosocomial Infection Diagnostic Test: Diagnosis of bacterial infections

Detailed Description:

Aim of the work

  1. To estimate the frequency and risk factors of nosocomial chest infections in cirrhotic patients .
  2. To determine the causative pathogens of nosocomial chest infections in patients with cirrhosis including fungal infections in order to establish our local empirical antimicrobial protocol.
  3. To define the impact of nosocomial chest infections on survival of our patients.
  4. To develop an effective and continuous surveillance program and infection control measures to reduce the burden of these infections as well as morbidity , mortality , hospital stay ,hospital cost and to achieve quality of care .
  5. To motivate pharmaceutical companies to create a new umbrella coverage of antimicrobials through the ongoing knowledge of the changes in microbial resistance pattern inside hospitals

Layout table for study information
Study Type : Observational
Estimated Enrollment : 20 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Nosocomial Bacterial and Fungal Chest Infections in Cirrhotic Patients
Estimated Study Start Date : June 2018
Estimated Primary Completion Date : May 2019
Estimated Study Completion Date : August 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Molds

Group/Cohort Intervention/treatment
Nosocomial infected cirrhotic patients Diagnostic Test: Diagnosis of bacterial infections
Cultures




Primary Outcome Measures :
  1. Frequency of nosocomial infection in patients with liver cirrhosis [ Time Frame: baseline ]
    nosocomial infection is one of predictors of bad outcome in liver cirrhosis



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
patient were known to have liver cirrhois and admitted at hospital secondary to any cause
Criteria

Inclusion Criteria:

  • All cirrhotic patients , decompensated , child pug score B or C ,may have Hepatocellular carcinoma , other comorbidities may present as (Diabetius mellitus , Hypertension , Heart disease and renal impairment ) , both sex and with clinical suspicion of chest infections acquired after 48 hours of admission

Exclusion Criteria:

  • Patients have any chronic chest disease
  • Patients have severe immunosuppression (neutropenia after chemotherapy or hematopoietic transplant, drug-induced immunosuppression in solid-organ transplant or cytotoxic therapy, and HIV-related disorders.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03413293


Contacts
Layout table for location contacts
Contact: Nariman zaghluol bakhiet, postgraduate 01005546130 narimandoctor@yahoo.com

Sponsors and Collaborators
Assiut University

Publications:
Layout table for additonal information
Responsible Party: NZBakhiet, resident doctor, Assiut University
ClinicalTrials.gov Identifier: NCT03413293     History of Changes
Other Study ID Numbers: NBFCIIHCP
First Posted: January 29, 2018    Key Record Dates
Last Update Posted: May 18, 2018
Last Verified: February 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Infection
Communicable Diseases
Cross Infection
Iatrogenic Disease
Disease Attributes
Pathologic Processes